Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642312 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
A Phase 3 study of Uveitic Macular Edema, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT05642312: Completed Phase 3 study of Uveitic Macular Edema, sponsored by Hoffmann-La Roche.
NCT05642312 is a Phase 3 study of Uveitic Macular Edema that has completed, run by Hoffmann-La Roche. The registered enrollment target is 245 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05642312, a Phase 3 study of Uveitic Macular Edema, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Conditions Studied
Interventions
- OTHER Sham
- DRUG Vamikibart
Study Locations (20)
Other
- LKH-Univ.Klinikum Graz - Graz
- Kepler Universitätskliniken GmbH - Med Campus III - Linz
- Medizinische Universitat Wien - Vienna
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University Investigational Drug Services - Columbus
Texas
- Austin Clinical Research LLC - Austin
- Texas Retina Associates - Dallas
California
- Kaiser Permanente Southern California - Los Angeles
Colorado
- Colorado Retina Associates, PC - Lakewood
Florida
- Retina Vitreous Associates of Florida - St. Petersburg
Maryland
- Cumberland Valley Retina PC - Hagerstown
Minnesota
- VitreoRetinal Surgery, PLLC. - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 3 |
What the finished NCT05642312 record still lists
NCT05642312 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Uveitic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT05642312 names 20 study sites across 16 states, led by Other, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05642312 about?
NCT05642312 is a clinical study titled "A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema". This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
What is the current status of trial NCT05642312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2023-01-09. Estimated completion is 2025-07-09.
What conditions does trial NCT05642312 study?
This clinical trial studies the following conditions: Uveitic Macular Edema.
What interventions are being tested in trial NCT05642312?
The interventions under investigation include: Sham (OTHER), Vamikibart (DRUG).
Who is sponsoring clinical trial NCT05642312?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642312 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05642312's enrollment target sits among peer trials
245 1267th of 2000 higher than 732 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI